Recital 30, Regulation (EU) 2016/161

In forcesince 2 Oct 2015cited 2×

The structure of the repositories system should be such as to ensure that medicinal product verification is possible throughout the Union. This may require the transfer of data and information on a unique identifier between repositories within the repositories system. In order to minimise the number of necessary connections between repositories and ensure their interoperability, each national and supranational repository part of the repositories system should connect to and exchange data through a central repository acting as information and data router.

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision

    However, as the Advocate General observed, in essence, in point 139 of his Opinion, a parallel importer cannot rely on a general presumption of consumer resistance to relabelled medicinal products whose anti-tampering devices have been …

    17 Nov 2022 · 62020CJ0224

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    However, as the Advocate General observed, in essence, in point 139 of his Opinion, a parallel importer cannot rely on a general presumption of consumer resistance to relabelled medicinal products whose anti-tampering devices have been …

    17 Nov 2022 · 62020CJ0147